Fast-acting, non-invasive, and non-sedating

It's always nice when a bland, investor-focused summary of a company suddenly gives me immense cravings, as in this Motley Fool overview of Javelin Pharmaceuticals:

It has completed enrollment for the first of two planned pivotal phase 3 clinical trials in the U.S. for Rylomine, an intranasal form of morphine for pain, and the company expects to announce preliminary results by the end of June... Rylomine provides an alternative way to administer morphine that starts to work quicker than when it's taken orally and has effects similar to when it's given intravenously -- without the hassle of needles.

Javelin is also developing an intranasal formulation of ketamine (PMI-150) that's designed to provide fast-acting, non-invasive, and non-sedating pain relief.

In a perfect world, researchers would have my number on their speed dial for clinical trials of this type of thing.